{"webUser":null}

OncLive® On Air / FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS

View our embed guidelines

Sorry, your browser isn't supported.

We recommend upgrading to the latest Chrome, Firefox, Safari, or Edge.

You can visit our support center if you're having problems.